Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ADOT - BIOMODA: Profitable Technology with Purpose -- Ignore unavailable to you. Want to Upgrade?

To: smackdown who wrote (307)	1/6/1998 6:28:00 PM
From: Andrew T	Respond to of 4650

INTERNET ADDRESS:www.biomoda.comTECHNOLOGY:Biomoda, Inc. is a development stage company that plans to develop, manufacture and market porphyrin compounds for potential use in diagnosing and treating human diseases. The company is the exclusive worldwide licensee of its core lung cancer in vitro diagnostic and in vivo diagnostic and therapeutic technology. HOW DOES IT WORK?:Biomoda1s licensed photoreactive compund, (5,10,15,20 -TETRAKIS [4-Carboxyphenyl Porphine] (TCPP), is selectively taken up by neoplastic or fast-growing cells, such as cancer cells. When cells which have been treated with TCPP are viewed under a microscope and exposed to ultraviolet light, the cells which have taken up TCPP will fluoresce in the visible spectrum, thus making it a potentially useful diagnostic tool when viewed through a microscope. TCPP can also bind radioactive copper for potential use inside the body. The selective uptake properties of the TCPP are combined with the emissive properties of the isotope for potential diagnostic and therapeutic applications. MARKET FOCUS:Biomoda owns an exclusive worldwide license to patents obtained from the University of California, covering the use of synthetic porphyrin, TCPP, in diagnosing and treating cancer. In the United States, Biomoda plans to develop, manufacture and market products for the detection and treatment of lung cancer. APPLICATIONS:Biomoda plans to develop, manufacture and market three products as follows: _In Vitro/First-generation products: Reagents for diagnosing cancer in tissue specimens as performed in the cytology laboratory. _In Vivo/Second-generation products: TCPP complexed with radioactive copper. Two separate formulations will be used; one for diagnosing and the other for treating lung cancer. MARKET POTENTIAL:According to the Theta Research Corporation, the cancer therapeutics market is expected to exceed $3 billion by 1998. The in vivo imaging and radiopharmaceutical market is expected to exceed $1.3 billion. KEY MANAGEMENT:Jeffrey L. Garwin, M.D., Ph.D. - CEO and Chief Technical Officer Irv Weiman - Chairman and Chief Financial Officer Ari Ma1ayan - Vice President, Technical Development SCIENTIFIC ADVISORY BOARD:Geno Saccomanno, M.D., Ph.D. - St. Mary1s Hospital Edward Ellinwood, M.D., Ph.D. - St. Mary1s Hospital Buck A. Rhodes, Ph.D. FINANCIAL DATA: Direct Public Offering: November 8, 1996 CORPORATE MILESTONES:November, 1995Biomoda and the University of California Exclusive Patent LicenseJanuary, 1995Biomoda and the University of California Small Business Cooperative Research and Development AgreementJanuary, 1996Biomoda and Shanghai Center for research and development of New Drugs (SCOND) Letter of Intent to set up a joint venture to research and develop, manufacture and market lung cancer detection and treatment products in the People1s Republic of China.Pending:Biomoda and the Pulmonary Division, Dept. of Medicine, University of New Mexico Initiation of Clinical Studies Biomoda and BioPharm Clinical Services Regulatory Support and Management